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Introduction: Transcatheter aortic valve implantation (TAVI) has evolved as an alternative
method for surgical valve replacement in high-risk patients. Initially the transfemoral (TF)
approach was used, later the transapical (TA) approach was adopted as an option for
selected patients. The aim of our study was to compare the safety and anatomical and
functional success of TAVI procedures with surgical aortic valve replacement (SAVR).
Material and methods: The study included 45 consecutive high-risk patients with symptomatic
severe aortic stenosis indicated for aortic valve intervention who met the entry criteria (age
475 years; logistic Euroscore 415%). The patients were allocated to one of three groups
according the type of procedure: SAVR (n ¼ 15), TAVI TA (n ¼ 15) and TAVI TF (n ¼ 15). The
groups did not differ in their preoperative characteristics except for myocardial infarction,
which was more common in the TAVI groups. The Edwards Sapien valve was implanted in the
TAVI patients and Edwards Perimount bioprosthesis was used in the SAVR patients. The TA
approach was used in patients who were not eligible for the TF approach.
Results: All procedures were technically successful. The prostheses used in the SAVR group
were smaller in size than those implanted in the TA and TF groups (SAVR, 22.2(21.7;22.8); TA,
24.0(23.6;24.3); TF, 25.0(24.6;25.3)). The TA group patients were exposed to radiation for a
shorter period and received a larger amount of contrast medium (TA, 9.7(9.0;10.5)min and
278.3(238.5;318.1)ml; TF, (15.0(13.7;16.4)min, 200.7(179.2;222.1)ml) in TF group). There were no
statistically significant differences in the duration of procedures, stay in the intensive care unit
and in the hospital, and intra- and post-operative complications among the groups. Early
mortality (30 days) was 2.2%. One patient died of clostridium sepsis on day 12 (early mortality,
2.2%). Another patient died due to the multi-organ failure on the 58th day of hospital stay. Five
other patients died during one-year follow-up (one-year survival rate, 86.3%). The functional
class highly improved in all the patients, of whom 80% were with NYHA classes I or II.
Conclusion: Our results show that TAVI is a safe method for treatment of aortic stenosis in high-
risk patients and its early results are comparable with surgical aortic valve replacement. The
TF and TA approaches are equally efficient, with similar outcomes and complication rates.
Provided these results are confirmed at long-term follow-up, it can be assumed that the
indication criteria for TAVI approaches will expand.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All
rights reserved.ch Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All rights reserved.
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Until recently, surgical valve replacement was the only
treatment for symptomatic aortic stenosis. Although this
method has achieved excellent results, for certain groups of
patients (those at advanced age or with serious co-morbid-
ities) it could present an increased risk of severe complica-
tions or even death. However, such patients could benefit
from a less invasive method, such as transcatheter aortic
valve implantation (TAVI). The Sapien valve (Edwards Life-
sciences, Inc., Irvine, California) is an expandable valve made
of bovine pericardium which is delivered into the target site
by means of a catheter. Calcified leaflets of the existing valve
are pushed laterally towards the annulus and the new valve is
firmly anchored in them. This procedure can be carried out
through either the retrograde transfemoral (TF) or the
antegrade transapical (TA) approach. The aim of this study
was to ascertain the safety of the TAVI procedure and to
compare its outcomes with those of surgical aortic valve
replacement (SAVR).2. Material and methods
The study comprised 45 patients with symptomatic severe
aortic stenosis in whom surgical valve replacement was
considered to be associated with high risk, as assessed by the
logistic EuroSCORE [1]. The contraindications included a
bicuspid aortic valve, ischaemic heart disease requiring
revascularization, left ventricular ejection fraction r20%
and severe (3þ) mitral or aortic regurgitation. Also, patients
with serious co-morbidities and an estimate of life expec-
tancy less than three years were not considered. The multi-
disciplinary team that included cardiac surgeons,
interventional cardiologists and cardiologists specialized in
echocardiography assessed all the patients and decided to
recommend the specific procedure to each patient. SAVR was
not recommended in patients with serious clinical co-
morbidities that are not measurable by EuroSCORE (worse
mental status, limited physical activity, etc.). In the TAVI
groups TF approach was considered as the first choice.
According to the procedure used, the patients were assigned
to the SAVR (n ¼ 15), TF (n ¼ 15) and TA (n ¼ 15) groups.
The characteristics of the patients before the procedure are
presented in Table 1. This shows that the group consisted of
elderly patients at high surgical risk (average age, 82.074.5
years; logistic EuroSCORE, 22.377.6), with more women than
men and with a high number of diabetic patients. Athero-
sclerotic coronary artery disease (CAD) was diagnosed in 45%
of them (18% of the patients with severe stenoses had
undergone revascularization, seven patients by means of
percutaneous intervention and one patient by coronary artery
bypass grafting). CAD did not influence the choice between
SAVR and TAVI. Renal failure was diagnosed by biochemical
tests in 29%. There were no significant differences in the
recorded characteristics among the groups, with the excep-
tion of myocardial infarction which occurred more often in
both TAVI groups.All patients were examined according to an established
protocol. In addition to routine clinical and laboratory
examination, this included CT angiography, transoesophageal
echocardiography (TEE), cardiac catheterization, coronarogra-
phy, aortography, and pelvic arterial angiography. The find-
ings were assessed by a multidisciplinary team of
cardiologists and cardiac surgeons who decided the type of
procedure to be performed in the patient. In TAVI procedures,
the TF approach was given priority. The TA approach was
used when femoral artery diameters were not large enough,
severe calcifications were present or pelvic and femoral
arteries were affected by serious atherosclerotic disease. All
the procedures were carried out in the hybrid operating
theatre.
TAVI procedures were performed by the technique de-
scribed in the literature [2,3] with the use of Edwards-Sapien
or Sapien XT aortic valves. The definitive size of the valve to
be implanted was determined on the basis of intra-operative
TEE, with a 23-mm valve for aortal annuli 17–21 mm in
diameter, and a 26-mm valve for annuli 22–25 mm in
diameter. When an annular diameter of 21–22 mm made the
decision difficult, the final decision was based on the degree
of regurgitation of contrast medium at angiography during
balloon dilatation of the valve. After the procedure, the
patients received an anti-platelet therapy with acetylsalicylic
acid (100 g daily) and clopidogrel (75 g daily).
SAVR was carried out in cardiopulmonary bypass during
cardiac arrest with crystalloid cardioplegia. The bioprosthetic
valve was sutured in a supra-annular position, using sutures
with pledgets from the ventricular side. The patients received
warfarin therapy for 3 months post-operatively. Their follow-
ups at regular intervals included clinical examination,
laboratory tests and transthoracic echocardiography.2.1. Statistical analysis
Continuous parameters were described using the mean and a
95% confidence interval, and categorial parameters were
described by absolute and relative numbers. In case of non-
normal data distribution, logarithmic transformation was
applied and data were described by the geometric mean with
a 95% confidence interval. The significance of differences
amongst the groups of patients was tested by ANOVA and ML
Chi-square tests for continuous and categorial parameters,
respectively. In the case of a significant difference amongst all
groups, an analysis of homogenous patient groups was
performed using a post hoc test with the Bonferroni correc-
tion for multiple comparisons. The difference between time
points was evaluated using the t-test for paired values. The
level of statistical significance was set at po0.05. All analyses
were carried out with the software SPSS 19.0.1 (IBM, 2010).3. Results
No complication was recorded during surgical aortic valve
replacement and all TAVI procedures were technically suc-
cessful. The bioprosthetic valves used at SAVR were smaller
in size than those at TAVI. The TF approach was associated
Table 1 – Pre-operative patient characteristics.
Total number of
patients ¼ 45
SAVR group
n ¼ 15
TA group
n ¼ 15
TF group
n ¼ 15
p
Age 82.0(80.8;83.2) 82.1(81.2;82.9) 80.3(79.0;81.6) 83.6(82.4;84.8) 0.132
EuroSCORE 22.3(20.4;24.3) 18.6(17.3;19.9) 23.5(21.2;25.9) 24.9(23.0;26.7) 0.058
NYHA
II 6(13.3%) 3(20.0%) 1(6.7%) 2(13.3%) 0.572
III 29(64.4%) 10(66.7%) 11(73.3%) 8(53.3%)
IV 10(22.2%) 2(13.3%) 3(20.0%) 5(33.3%)
Body weight 71.6(68.3;74.8) 74.5(71.7;77.4) 73.2(70.0;76.4) 66.9(63.4;70.4) 0.211
Body height 161.0(158.1;163.9) 161.5(159.1;163.9) 160.3(157.1;163.5) 161.2(158.0;164.4) 0.961
Body mass index 27.6(26.5;28.8) 28.7(27.5;29.9) 28.5(27.5;29.5) 25.7(24.6;26.8) 0.106
Men/women 14/31(31.1/68.9%) 6/9(40.0/60.0%) 4/11(26.7/73.3%) 4/11(26.7/73.3%) 0.666
Obesity 14(31.1%) 5(33.3%) 6(40.0%) 3(20.0%) 0.472
Hyperlipidemia 19(42.2%) 5(33.3%) 8(53.3%) 6(40.0%) 0.528
Hypertension 35(77.8%) 11(73.3%) 11(73.3%) 13(86.7%) 0.577
Smoking habits 5(11.1%) 1(6.7%) 1(6.7%) 3(20.0%) 0.430
Diabetes mellitus 19(42.2%) 6(40.0%) 7(46.7%) 6(40.0%) 0.913
CAD
1 vessel 10(22.7%) 3(20.0%) 3(21.4%) 4(26.7%) 0.097
2 vessels 7(15.9%) 1(6.7%) 5(35.7%) 1(6.7%)
3 vessels 3(6.8%) 0(0.0%) 2(14.3%) 1(6.7%)
Main stem 5(11.4%) 1(6.7%) 4(28.6%) 0(0.0%) 0.029n
Status post MI 7(15.6%) 0(0.0%)a 3(20.0%)b 4(26.7%)b 0.039n
Status post PCI 7(15.6%) 2(13.3%) 2(13.3%) 3(20.0%) 0.849
Status post CABG 1(2.2%) 0(0.0%) 1(6.7%) 0(0.0%) 0.326
Peripheral vascular
disease
1(2.2%) 0(0.0%) 0(0.0%) 1(6.7%) 0.326
Status post PAR 3(6.7%) 1(6.7%) 0(0.0%) 2(13.3%) 0.233
TIA/ CVA 7(15.6%) 3(20.0%) 2(13.3%) 2(13.3%) 0.849
Renal failure 13(28.9%) 4(26.7%) 5(33.3%) 4(26.7%) 0.899
CAD—coronary artery disease, MI—myocardial infarction, PCI—percutaneous coronary intervention, CABG—coronary artery bypass grafting,
TIA—transient ischaemic attack, CVA—cerebrovascular accident, PAR—peripheral arterial reconstruction.
a, b—index numbers denote statistical differences between two patient groups (post hoc test with Bonferroni correction).
n Significant difference.
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medium volume used than the TA approach (Table 2).
Procedural complications were found in seven patients
(Table 3). In two patients, a rapid ventricular stimulation
during the implantation procedure resulted in ventricular
fibrillation requiring a short-term indirect cardiac massage
followed by external defibrillation. In one TF group patient, the
valve failed to be pushed through the sheath and the whole
device had to be removed; however, the valve remained
undamaged and was implanted by means of another catheter.
In one patient, implantation through the TF approach led to
pelvic artery rupture. This patient was urgently operated on
and the ruptured artery was replaced with a vascular
prosthesis. One TA group patient experienced persisting
post-operative grade II regurgitation which, during the post-
operative period, slightly progressed with aggravation of
symptoms. The patient had to undergo reoperation. During
the procedure it appeared that the valve was implanted at a
position that was too low and a part of the native leaflet folded
over the implanted valve and thus interfered with diastolic
valve closure. The Sapien valve was removed and the native
valve was replaced with a conventional bioprosthetic valve.The duration of mechanical ventilation, and the length of
stay at the intensive care unit and in the hospital did not
differ among the groups. More than half of the patients had at
least one post-operative complication, with similar figures in
all groups (Table 4). Six patients had acute renal failure with
the necessity of using renal replacement therapy. Six patients
experienced respiratory failure and accordingly had to under-
go repeated intubation or remain on mechanical ventilation
for more than three days. Four patients had neurological
complications. Three patients had reoperations, one from the
SAVR (due to tamponade) and two from the TA group; of
these, one was the patient with valve replacement described
above and the other had reoperation for bleeding from the
cardiac apex.
One patient after SAVR died of clostridium sepsis in the
early post-operative period (on day 12). One very high risk
patient (EuroSCORE, 42) in the TF group died due to multi-
organ failure during the initial hospital stay on day 58. Four
more patients died due to cardiac reasons, though with well-
functioning aortic valves, on post-operative days 41, 235, 274
and 305, respectively. One patient died of a cerebrovascular
accident on day 69 after procedure.
Table 2 – Surgical characteristics.
Valve size (mm) Total number of
patients ¼ 45
SAVR group
n ¼ 15
TA group
n ¼ 15
TF group
n ¼ 15
p
20 4 4
21 4 4
23 18 3 10 5
25 3 3
26 15 5 10
27 1 1
Mean 23.7(23.2;24.2) 22.2(21.7;22.8)a 24.0(23.6;24.3)b 25.0(24.6;25.3)b o0.001n
Operative time (min) 148.9(139.5;158.9) 143.8(135.3;152.8) 137.3(130.6;144.3) 167.2(155.2;180.3) 0.078
Radiation exposure time
(min)
12.1 (10.5;13.9) – 9.7(9.0;10.5) 15.0(13.7;16.4) o0.001n
Contrast medium volume
(ml)
239.5 (193.7; 285.3) – 278.3(238.5;318.1) 200.7(179.2;222.1) o0.001n
a, b—index numbers denote statistical differences between two patient groups (post hoc test with Bonferroni correction).
n Significant difference.
Table 3 – Intra-operative complications.
Total number of
patients ¼ 45
SAVR group
n ¼ 15
TA group
n ¼ 15
TF group
n ¼ 15
p
Total 7(15.6%) 0 3(20.0%) 4(26.7%) 0.305
Ventricular fibrillation 2(4.4%) 0(0.0%) 1(6.7%) 1(6.7%) 0.434
AoR (grade 2 and more) 2(4.4%) 0(0.0%) 1(6.7%) 1(6.7%) 0.434
Local/groin, apex,
sternum/
1(2.2%) 0(0.0%) 0(0.0%) 1(6.7%) 0.326
Device failure 1(2.2%) 0(0.0%) 0(0.0%) 1(6.7%) 0.434
Valve malposition 1(2.2%) 0 1(6.7%) 0 0.434
AoR—aortic regurgitation.
Table 4 – Postoperative results.
Total number of
patients ¼ 45
SAVR group
n ¼ 15
TA group
n ¼ 15
TF group
n ¼ 15
p
MPV duration (hours) 8.67(7.17;10.17) 10.6(9.0;12.1) 7.89(6.71;9.08) 7.46(5.76;9.16) 0.321
ICU stay (days) 7.69(6.40;9.21) 7.76(6.81;8.82) 8.60(6.92;10.63) 6.81(5.57;8.28) 0.671
Hospital stay (days) 14.4(12.6;16.3) 13.7(12.4;15.1) 15.3(13.3;17.7) 14.1(12.2;16.3) 0.815
Complications 24(53.3%) 7(46.7%) 11(73.3%) 6(40.0%) 0.145
Fever 10(22.2%) 4(26.7%) 5(33.3%) 1(6.7%) 0.147
ARI 6(13.3%) 2(13.3%) 3(20.0%) 1(6.7%) 0.549
Respiratory failure 6(13.3%) 2(13.3%) 2(13.3%) 2(13.3%) 1.000
Impaired wound
healing
5(11.4%) 0(0.0%)a 1(6.7%)a 4(26.7%)b 0.036n
Reoperation 3(6.6%) 1(6.7%) 2(13.3%) 0(0.0%) 0.233
TIA/CVA 4(8.8%) 1(6.7%) 1(6.7%) 2(13.3%) 0.771
Mortality
Early (up to 30 day) 1(2.2%) 1(6.7%) 0 0 0.326
Annual 6(13.3) 2(13.3%) 2(13.3) 2(13.3%) 1.000
MPV—mechanical pulmonary ventilation, ICU—intensive care unit, ARI—acute renal insufficiency, TIA—transient ischaemic attack,
CVA—cerebrovascular accident.
a, b—index numbers denote statistical differences between two patient groups (post hoc test with Bonferroni correction).
n Significant difference.
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show any differences among the groups. After surgery, a
significant decrease in aortic valve gradients and an increase
in the aortic valve area were recorded in comparison with the
pre-operative values in all groups. These values remained
unchanged during follow-up. Neither the ejection fraction nor
the size of the left ventricle was significantly changed after
surgery. Both the interventricular septum and the posterior
left ventricular wall significantly decreased in thickness.
Grade II regurgitation due to periprosthetic leakage was found
in two patients one month after surgery, but this had no
effects on symptoms or left ventricular function. Regurgita-
tion in the remaining patients was not more than grade I
(Table 5). The New York Heart Association (NYHA) functional
classification improved after surgery, with nearly 80% of the
patients having NYHA classes I or II (Fig. 1).4. Discussion
The transcatheter aortic valve implantation (TAVI) was first
used nearly ten years ago. Thanks to huge advances in
technology allowing for much improvement [4], the numbers
of patients with TAVI have grown exponentially and today
they amount to tens of thousands. Two types of valves are
available in the market. One is a self-expanding valve
prosthesis suitable only for the retrograde transarterial
approach (CoreValve, Medtronic Inc., Minneapolis, Minn),
the other is an balloon expandable valve made of bovine
pericardium (Edwards Sapien) which can be used for both the
retrograde transfemoral and the antegrade transapical
approach. Because of its greater versatility, the Edwards
Sapien valve was chosen for our study. Our decision was
supported by the literature data showing that TAVI, with both
the TF and the TA approaches, makes it possible to treat
50–76% of the patients who have been inoperable by SAVR
because of a high surgical risk [5,6]. These surgically inoper-
able patients have very poor prognosis, even if in the
Placement AoRtic TraNscathetER (PARTNER) Trial, the Cohort
B patients showed very good early outcomes, but some doubts
about their reproducibility have appeared later [7,8].
A decision for either SAVR or TAVI should be made by a
multidisciplinary team and should be based on a thorough
evaluation of the patient’ health status, and particularly co-
morbidities. When indicating TAVI, the patient’s life expec-
tancy should also be taken into account since, at present, the
cost of valves is enormous and therefore limits their use in
our circumstances. A judicious selection of patients for TAVI
is the reason why Czech centres can report better results than
are those of large international studies [9–11]. In this study
there was no early mortality and one-year survival rate was
86.3%, while evidence from the relevant literature suggests an
early mortality rate up to 10% and one-year survival rate of
about 80% [12–15]. Other studies describe even higher
mortality. In the Vancouver study, for instance, the early
mortality rate was 16.9% and the two-year survival rate was
66.3% [16]. With growing experience, however, clinical out-
comes are improving [17].
In TAVI procedures, the TF approach is usually described as
the method of choice because it is less invasive. On the otherhand, it needs more manipulation with catheters in the aorta
and therefore carries a higher risk of damage to the vascular
wall or of embolization with corpuscular material. The TA
approach is used when the patient has stenotic, calcified or
tortuous pelvic arteries. Both approaches are reported to be
used at almost the same frequency although some centres
may prefer one of the approaches over the other [11,14,18].
Implantation of the valve is less technically demanding via
the TA approach because the device is shorter and thus easier
to manipulate. This is a probable explanation of a tendency to
shorter operative time and exposure to radiation for a shorter
time, as recorded in our study. Certain concern about
potential injury to the left ventricular wall and a subsequent
decrease in its systolic function in the TA approach was not
found to be justified. The benefits of eliminating aortic
stenosis much exceed the threat of minor injury to the left
ventricular apex and will be manifested by a post-operative
increase in ejection fraction [19]. However, certain caution
should always be adopted because serious complications,
such as apical pseudoaneurysm, have been described [20].
The overall short term-results, in terms of early complica-
tions and mortality, in the two TAVI groups are comparable,
which is in accordance with the relevant literature data.
When the outcomes were different, it was due to different
pre-operative risk factors and/or intra-operative complica-
tions [18]. This fact is documented by the data from the
SAPIEN Aortic Bioprosthesis European Outcome (SOURCE)
registry recording, in a group of 1038 patients, a higher
mortality rate in patients treated with use of the TA approach.
However, these patients suffered from more co-morbidities
and had a significantly higher logistic EuroSCORE [14].
A comparison of the two procedures (surgical vs. trans-
catheter) in a randomized trial has so far been reported in one
prospective study only. In the PARTNER trial, Cohort A
included high-risk patients with severe aortic stenosis
assigned to undergo either TAVI or SAVR. The primary
endpoint was death from any cause at 1 year and, according
to this criterion, the TAVI technique was not inferior to
traditional surgical treatment. Early mortality was 3.4% in the
TAVI group and 6.5% in the surgical group; one-year mortality
was 24.2% in the TAVI and 26.8% in the surgical group.
However, there were differences in early complications. The
TAVI group had a significantly higher rate of major vascular
complications, and the surgical group had higher rates of
major bleeding events and new-onset arterial fibrillation [21].
The results of our study assessed by the survival rate are in
full agreement with those of the PARTNER trial. The one-year
mortality rate was the same in all our groups, but on the
whole was lower (13.3%) than in the PARTNER trial.
In our study, renal failure requiring a temporary renal
replacement therapy was the most frequent post-operative
complication. It appeared particularly in the first patients in
whom larger volumes of contrast medium were used. After this
experience, the necessary medium amount was reduced to
minimum, which resulted in fewer cases of renal failure. Central
nervous system involvement was the most serious complica-
tion. It was slightly more frequent in the TAVI procedure,
particularly with the TF approach, but the difference, as
compared with the surgical procedure, was not significant. This
is consistent with the literature data [21].
Table 5 – Echographic parameters before surgery and at 1 and 12 months after surgery.
Total number of patients ¼ 45 SAVR group n ¼ 15 TA group n ¼ 15 TF group n ¼ 15 p
Peak gradient (mmHg)
Before operation 84.6(78.6;90.6) 87.7(80.2;95.1) 79.9(75.3;84.6) 86.2(80.3;92.1) 0.638
1 month 20.2(18.5;21.8) 23.2(21.2;25.1) 19.9(18.8;21.0) 17.9(16.2;19.5) 0.091
12 months 19.8(17.9;21.7) 21.5(19.2;23.8) 19.9(18.2;21.5) 17.4(15.6;19.2) 0.430
Before1 month o0.001n o0.001n o0.001n o0.001n
1 month 12 months 0.455 0.415 0.690 0.970
Before12 months o0.001n o0.001n o0.001n o0.001n
Mean gradient (mmHg)
Before operation 51.2(47.2;55.2) 53.0(48.1;57.9) 49.7(46.7;52.8) 50.8(46.7;54.9) 0.848
1 month 10.7(9.7;11.7) 12.0(10.9;13.1) 10.7(10.0;11.4) 9.5(8.5;10.5) 0.229
12 months 10.1(9.1;11.2) 11.0(9.7;12.3) 10.1(9.4;10.9) 9.00(8.11;9.89) 0.494
Before1 month o0.001n o0.001n o0.001n o0.001n
1 month 12 months 0.134 0.309 0.156 0.782
Before12 months o0.001n o0.001n o0.001n o0.001n
AVA (cm2)
Before operation 0.61(0.56;0.66) 0.69(0.64;0.74) 0.60(0.55;0.64) 0.54(0.49;0.59) 0.092
1 month 1.93(1.82;2.03) 2.01(1.88;2.14) 1.82(1.74;1.89) 1.95(1.85;2.05) 0.458
12 months 1.78(1.68;1.89) 1.70(1.58;1.82) 1.79(1.69;1.90) 1.87(1.79;1.95) 0.623
Before1 month o0.001n o0.001n o0.001n o0.001n
1 month 12 months 0.051 0.072 0.986 0.276
Before12 months o0.001n o0.001n o0.001n o0.001n
AVAi (cm2/m2)
Before operation 0.34(0.32;0.37) 0.39(0.36;0.42) 0.33(0.31;0.35) 0.31(0.28;0.34) 0.112
1 month 1.10(1.05;1.16) 1.14(1.07;1.21) 1.04(0.99;1.08) 1.13(1.09;1.18) 0.402
12 months 1.01(0.94;1.07) 0.91(0.85;0.97) 1.01(0.93;1.08) 1.12(1.07;1.17) 0.160
Before1 month o0.001n o0.001n o0.001n o0.001n
1 month 12 months 0.090 0.022n 0.820 1.000
Before12 months o0.001n o0.001n o0.001n o0.001n
EF (%)
Before operation 55.7(52.5;59.0) 58.0(54.7;61.3) 56.6(53.8;59.4) 52.6(49.0;56.2) 0.482
1 month 57.5(54.0;60.9) 62.1(59.2;64.9) 55.7(52.3;59.2) 55.1(51.3;59.0) 0.330
12 months 58.2(55.7;60.8) 58.8(55.9;61.8) 58.4(56.0;60.9) 57.2(54.8;59.6) 0.924
Before1 month 0.182 0.107 0.770 0.244
1 month 12 months 0.436 0.145 0.561 0.474
Before12 months 0.560 0.835 0.722 0.616
LVEDD (mm)
Before operation 46.6(45.1;48.1) 47.5(46.1;48.9) 45.1(43.9;46.4) 47.2(45.3;49.1) 0.512
1 month 46.1(44.5;47.6) 45.4(43.9;46.9) 45.9(44.5;47.3) 46.9(45.1;48.6) 0.809
12 months 44.6(42.9;46.3) 45.5(43.5;47.6) 43.4(41.7;45.0) 45.1(43.9;46.3) 0.665
Before1 month 0.450 0.090 0.281 0.755
1 month 12 months 0.353 0.921 0.136 0.940
Before12 months 0.168 0.182 0.369 0.901
LVESD (mm)
Before operation 33.1(31.1;35.1) 33.0(31.0;35.0) 31.7(30.1;33.2) 34.7(32.3;37.0) 0.569
1 month 32.0(30.1;34.0) 30.3(28.5;32.1) 32.4(30.6;34.3) 33.1(30.9;35.4) 0.612
12 months 30.9(29.1;32.8) 31.5(29.1;33.8) 30.1(28.4;31.7) 31.5(30.2;32.8) 0.846
Before1 month 0.162 0.064 0.502 0.204
1 month 12 months 0.940 0.429 0.180 0.460
Before12 months 0.209 0.353 0.471 0.743
IVS (mm)
Before operation 15.3(14.8;15.7) 14.6(14.2;15.0) 15.6(15.3;15.9) 15.6(15.0;16.2) 0.223
1 month 13.9(13.4;14.3) 13.8(13.4;14.3) 13.7(13.2;14.2) 14.0(13.5;14.5) 0.922
12 months 13.4(12.9;13.8) 13.2(12.8;13.6) 13.4(13.1;13.8) 13.4(12.9;13.9) 0.947
Before1 month o0.001n 0.188 0.005n 0.010n
1 month 12 months 0.033n 0.120 0.351 0.260
Before12 months o0.001n 0.015n o0.001n 0.031n
PW (mm)
Before operation 13.7(13.2;14.1) 13.4(13.1;13.7) 13.6(13.1;14.0) 14.0(13.5;14.5) 0.646
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 7 6 – e 8 3 e81
Table 5 (continued )
Total number of patients ¼ 45 SAVR group n ¼ 15 TA group n ¼ 15 TF group n ¼ 15 p
1 month 13.2(12.8;13.5) 12.9(12.6;13.3) 13.2(12.8;13.6) 13.3(13.0;13.7) 0.766
12 months 12.2(11.9;12.5) 11.8(11.5;12.1) 12.6(12.4;12.7) 12.2(11.9;12.4) 0.166
Before 1 month 0.034n 0.124 0.454 0.125
1 month 12 months o0.001n 0.026n 0.050 0.003n
Before 12 months o0.001n 0.002n 0.024n 0.009n
AVA—aortic valve orifice area, AVAi—indexed aortic valve orifice area, EF—left ventricular ejection fraction, LVEDD—left ventricular end-
diastolic diameter, LVESD—left ventricular end-systolic diameter, IVS—interventricular septum thickness, PW—posterior wall thickness.
n Significant difference.
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Fig. 1 – Patients’ functional status before and after surgery.
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 7 6 – e 8 3e82Echographic examination showed a decrease in aortic valve
gradients and an increase in the aortic valve orifice area. Our
results confirmed the literature information on very low
gradients in TAVI implantation even though the leaflets of the
native calcified valve remained in place and were merely
pushed aside with a bioprosthetic valve. The gradients were
lower than in surgical replacement, in which the whole
calcified valve is removed, but the difference was not
significant. This can probably be explained by a rigid annulus
of the bioprosthesis which, even with supra-annular implan-
tation, presents an obstruction to blood flow. The same
results have been reported by Clavel et al. [22] in a larger
patient group; the mean and peak gradient values (10 mmHg
and 13 mmHg, respectively) in their study correspond
with ours.4.1. Study limitation
Due its focus on the population of the Czech Republic the
study is limited in the sample size and subsequently
in its statistical power; this fact was taken into consideration
during the interpretation and discussion of statistical
results.5. Conclusions
Our results, in agreement with the literature data, show that
TAVI is a safe method of treating aortic stenosis in high-risk
patients. Its early outcomes are very good and fully compar-
able with the traditional surgical aortic valve replacement.
The use of either a TF or a TA approach is equivalent. The
overall results and frequency of complications are also
similar in both methods [23]. If a long-term follow-up
confirms these results, it can be anticipated that the indica-
tions for TAVI will expand to include lower-risk patients [24].
In order to be truly beneficial to patients indicated for it, the
transcatheter valve therapy needs to keep to the guidelines
published, in a joined expert consensus document, by the
American College of Cardiology Foundation and the Society of
Thoracic Surgeons in 2011 [8]. This document recommends
the establishment of regional heart centres specializing in
TAVI procedures, existence of multidisciplinary, well coop-
erating specialist teams, and establishment of central data
registries for long-term result reporting. This will allow for
result interpretation after consensus of all experts and the
establishment of relevant educational programmes in this
field. In the Czech Republic, most of the recommendations
have been fulfilled or are currently implemented (with the
exception of a systematic educational programme), which
testifies to a high standard of health care in cardiology and
cardiac surgery.Acknowledgement
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